Can Pfizer's new drug clip top-selling Humira?
The pharma wins US approval for a new rheumatoid arthritis pill, but Abbott's existing treatment isn't likely to suffer a meaningful hit to sales anytime soon.
With Xeljanz, Pfizer is believed to have a potential blockbuster -- a drug that potentially generates a few billion dollars a year in revenue, according to Wall Street analysts.
Humira is poised to become the world's biggest-selling drug.
RBC Capital Markets analyst Glenn Novarro predicts Humira sales will top more than $9 billion this year and more than $10 billion in 2013. He does not plan to immediately change his forecast for the drug based on the approval of Pfizer's Xeljanz.
"We do not expect the convenience benefit of an oral to outweigh Humira's long-term efficacy and safety track record," Novarro says in a note to clients Wednesday. He has a buy rating on Abbott’s stock.
Indeed, Pfizer's drug carries a number of warnings, including risk of infections, tuberculosis and cancer. As part of its drug approval, Pfizer is required to carry out a plan to evaluate and mitigate the risks to patients. At almost $25,000 a year, the Pfizer drug is priced at a slight discount to the injected therapies.
Xeljanz, also known as tofacitinib, is part of a class of drugs known as JAK inhibitors. The Pfizer drug is approved by the Food and Drug Administration to treat patients with moderate to severe rheumatoid arthritis who are intolerant or can’t be treated with an older drug, methotrexate.
Other companies are studying JAK inhibitors. Eli Lilly (LLY) and Incyte (INCY) are studying a drug to treat rheumatoid arthritis. Incyte’s JAK inhibitor Jakafi was approved by the FDA last year for the blood cancer myelofibrosis. YM Biosciences (YMI) is in the early stages of testing a JAK inhibitor for inflammatory diseases, including rheumatoid arthritis, and cancer. The drugs are designed to inhibit a family of enzymes known as Janus kinases, which are linked to certain diseases.
Considered a promising new therapy, Pfizer's drug is approved at a crucial point for the company. For years, Pfizer relied on the cholesterol drug Lipitor, which has been the world's top-selling drug until recent generic competition. Pfizer desperately needs new blockbusters to fill the void of Lipitor and other older drugs.
Shares of Pfizer fell about 1% to $24.30 in morning trading Wednesday as the broader market also dipped. The stock is up more than 12% in 2012. Abbott, which plans to break into two separate companies later this year, fell almost 2% to $63.77. The company's shares are up more than 13% this year. Incyte gained 1% to $17.89 and Lilly fell 1% to $48.43.
More from Minyanville
Copyright © 2014 Microsoft. All rights reserved.
The Ukraine crisis festers and other fresh concerns boil to the surface, knocking down markets and giving volatility some life.
VIDEO ON MSN MONEY
Top Stocks provides analysis about the most noteworthy stocks in the market each day, combining some of the best content from around the MSN Money site and the rest of the Web.
Contributors include professional investors and journalists affiliated with MSN Money.
Follow us on Twitter @topstocksmsn.